Holly Reichard

This inventor holds 24 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Holly Reichard. Retrieved from https://idiyas.com/inventor/holly-reichard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 3)

% Patents Active = 75.0

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 13)

Average Co-Inventor Count = 6.4

ph-index = 4

Forward Citations = 48(Granted Patents)

Company Filing History:

24 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Azole-Fused Pyridazin-3(2H)-One

GPR139 Modulators

GPR6 Modulators

Tetrahydropyridopyrazines

5-HT3 Receptor Antagonists

Quinoxaline Derivatives

Substituted Pyrido[3,4-B]Pyrazines

Pyrazines

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12370192 - Azole-fused pyridazin-3(2H)-one derivatives (2025-07-29),

2. 11173161 - 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 (2021-11-16),

3. 10738046 - Substituted pyrido[3,4-b]pyrazines as GPR6 modulators (2020-08-11),

4. 10597392 - Tetrahydropyridopyrazines as modulators of GPR6 (2020-03-24),

5. 10561662 - 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 (2020-02-18),

6. 10407443 - 5-HT3 receptor antagonists (2019-09-10),

7. 10406157 - Tetrahydropyridopyrazine modulators of GPR6 (2019-09-10),

8. 10273225 - Pyrazines as modulators of GPR6 (2019-04-30),

9. 10179783 - Tetrahydropyridopyrazines as modulators of GPR6 (2019-01-15),

10. 10159677 - 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 (2018-12-25),

11. 10125145 - 5-HT3 receptor antagonists (2018-11-13),

12. 10077266 - Substituted pyrido[3,4-b]pyrazines as GPR6 modulators (2018-09-18),

13. 10000468 - Pyrazines as modulators of GPR6 (2018-06-19),

14. 9770452 - Quinoxaline derivatives as GPR6 modulators (2017-09-26),

15. 9770450 - 4-OXO-3,4-dihydro-1,2,3-benzotriazine as modulators of GPR139 (2017-09-26),

Title: The Innovative Contributions of Holly Reichard in Pharmaceutical Development

Introduction

Holly Reichard, based in San Diego, CA, is a prominent inventor recognized for her significant contributions to the field of pharmaceuticals. With an impressive total of 23 patents, Holly has demonstrated her commitment to innovation and the advancement of medical treatments.

Latest Patents

Holly’s latest patents reflect her focus on novel compounds relevant to receptor modulation. One of her notable inventions is related to “4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139.” This invention outlines a method for treating diseases associated with GPR139 by utilizing specific compounds as agonists. It also includes the pharmaceutical compositions, processes for synthesizing these compounds, and the necessary intermediates.

Another significant patent features “Substituted pyrido[3,4-b]pyrazines as GPR6 modulators.” This patent provides a new class of compounds that are useful as modulators of GPR6, alongside pharmaceutical compositions, methods for treating related conditions, and the synthesis processes of these compounds.

Career Highlights

Holly is currently affiliated with Takeda Pharmaceutical Company Limited, where she leverages her expertise to develop groundbreaking treatments. Her work has notably influenced drug discovery and development, paving the way for innovative therapies in various therapeutic areas.

Collaborations

Throughout her career, Holly has worked alongside esteemed colleagues such as Holger Monenschein and Stephen A Hitchcock. Their collaborative efforts have enhanced the research landscape in receptor modulation and have been crucial in advancing the understanding of various drug targets.

Conclusion

Holly Reichard's innovative spirit and dedication to her work have made her a key figure in the pharmaceutical industry. With her ongoing research and numerous patents, she continues to contribute significantly to medical science, ultimately improving patient outcomes through innovative drug development.

Profile summary based on public USPTO records.